License and Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended June 30,				Six months ended June 30,
Partner	Drug or Drug Candidate	2017		2016		2017		2016
AstraZeneca AB	MOVANTIK® and MOVANTIK® fixed-dose combination program	$	1,600	$	—	$	4,600	$	28,000
Amgen, Inc.	Neulasta®		1,250		1,250		2,500		2,500
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		357		357		714		714
Daiichi Sankyo Europe GmbH	ONZEALDTM (NKTR-102)		216		3,258		431		3,258
Roche	MIRCERA®		—		1,914		—		3,842
Baxalta Incorporated	ADYNOVATE®		45		207		45		313
Other			1,356		1,284		2,626		3,830
License, collaboration and other revenue		$	4,824	$	8,270	$	10,916	$	42,457